PLOS Medicine · 18 Nov 2026
Loss to follow-up during tuberculosis treatment and 5-year mortality in Brazil: A target trial emulation
Evelyn Lepka de Limah-index 1, Ana Angélica Lindoso, Giovanna Mariah Orlandi, Suely Fukasava, Catia Martinez, Julio Crodah-index 20, C. Robert Horsburgh, Otavio Ranzani, Meredith B. Brooks, Jason R. Andrewsh-index 63
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- OpenAlex0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background Loss to follow-up (LTFU) during tuberculosis treatment is a major programmatic gap, but how much excess mortality it causes has been difficult to estimate, because individuals who disengage differ from those who do not, and they must survive long enough to be recorded as having disengaged. Quantifying this excess and identifying which populations are at greatest risk are critical to informing program design and resource allocation. Methods and findings We followed 171,048 people aged 15 years or older starting a first course of tuberculosis treatment in São Paulo State, Brazil, between 2013 and 2023, linking surveillance and mortality registries; 20,830 (12.2%) were LTFU, defined as interruption of treatment for at least 30 consecutive days. Among those LTFU, 65% had received directly observed therapy (DOT). Using a clone-censor-weight target trial emulation, we contrasted two strategies over 60 months from the first day of treatment: disengagement at any point during the first 6 months and remaining in care throughout. Analyses were adjusted for age, sex, race, education, HIV status, diabetes, alcohol use, drug use, incarceration, homelessness, hospitalization at diagnosis, clinical form of tuberculosis, DOT, and municipality. A rolling landmark analysis addressed the timing of disengagement and cause-specific mortality excess. LTFU increased standardized 5-year mortality by 2.49 percentage points (95% CI [1.94, 3.17]). In a rolling landmark analysis, tuberculosis accounted for 61% of the 5-year excess mortality. Relative effects were largest in younger, stably housed individuals, whose baseline mortality was low; the largest absolute excess fell on people living with HIV (5.16 percentage points, 95% CI [3.76, 6.60]). The excess was similar for disengagement at any point in the first 4 months of treatment and attenuated thereafter. Limitations include the absence from the registry of severity markers such as radiographic extent and bacillary load, so residual confounding cannot be excluded. Conclusions Despite high DOT coverage, disengagement during the first 6 months of tuberculosis treatment was common and increased 5-year mortality under the stated identification assumptions, with the excess concentrated in deaths attributed to tuberculosis. Interventions that provide support throughout treatment should be tested for their effectiveness in sustaining engagement and reducing mortality.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Jason R. Andrews has the highest h-index among the authors (63).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (21)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 1 more reference
A free account opens the rest of the citing papers and references on every paper’s page.